Testimonials From How to Optimally Manage HTA Criteria & Processes in Europe
This training offers a solid knowledge foundation of HTA processes in Europe. It was a good investment of time and money.
SOBI
Mihaela Veringa, Director Global Access Policy & Governmental Affairs - Switzerland - November 2022 (live online course)I enjoyed interesting discussions with colleagues from different countries and backgrounds during the "How to Optimally Manage HTA Criteria & Processes in Europe" course run by CELforPharma. The course was conducted over 1 day and was full of learning, updates and networking opportunities.
Viatris
Taha Abdelrahman, Commercial Director - Tender Excellence - Emerging Markets - United Arab Emirates - November 2022 (live online course)The course was very complete and clear to understand better how to fulfil the market access challenges all over European countries. Lieven was very nice as educator to explain complex concepts in a very easy way.
Laboratoires Théa
Caroline Casanovas, PRMA & HEOR Manager - France - June 2022 (live online course)A lot of course materials and practical examples presented in an understandable manner with enough humour to keep us going. Lieven is an entertaining and knowledgeable trainer who answered all of our questions and offered excellent interaction opportunities. I really learned a lot on HTA and health economics. Thanks CELforPharma, and thank you Lieven!
Takeda
Tom Vanormelingen, Field Market Access Manager - The Netherlands - November 2021 (live online course)The course was well-structured and well presented by Prof. Lieven Annemans who gave us clear explanations and used illustrative materials to help us better grasp the key concepts of HTA. It was a very interactive course during the presentations and break-out sessions. Thanks and well done for a great training.
Amgen
Vincent Martichou, Government Affairs Manager ELMAC - Belgium - November 2021 (live online course)I’d definitely recommend this course to my colleagues. The content is very valuable and understandable. The exercises are also really good, and it’s very well organised. This training is one of the best online trainings I’ve attended in this COVID-19 period.
AstraZeneca
Ece Nalcakan, Market Access Manager - Turkey - November 2020 (live online course)This course is a fantastic introduction for people who are new in their role. Even for someone who is more experienced, this is a good opportunity to hear what we talk about on a daily basis articulated by an external perspective. Lieven is such a great speaker! The day flew by to the point where I wished we had a second day. His personality and deep knowledge really came through. The online format worked smoothly.
Novartis
Marisel Salzger, Global Market Access Director - Switzerland - November 2020 (live online course)The course content and the trainer are excellent! The interaction with the participants was nice, even on a digital platform. Thanks for all your efforts and for the great organisation.
AstraZeneca
Gulsen Cetin Cakir, Market Access Manager - Turkey - November 2020 (live online course)The course is highly valuable to jump into the HTA topic and to understand the multi-layered context. The lecturer combines relevant medical topics with health economic questions in an eloquent and flexible way. In summary, Prof. Annemans teaches the auditorium complicated things in a very entertaining way. The course is really fun.
Livanova
Claudia Lentner-Böhm, Director Market Access DACH - Germany - November 2019 (face-to-face course)The HTA course provides a great guidance of possible criteria and now the company should work to achieve best results. Great presenter encouraging discussions as always.
Celgene
Martina Jerabkova, Associate Director Global Market Access - Switzerland - November 2019 (face-to-face course)A very well-balanced course, not too technical but not too general, an HTA overview by an excellent teacher.
Novartis
Christophe Gerbeau, Head Market Access Early Products - France - May 2019 (face-to-face course)Very valuable, as this course provides you with a good theoretical foundation as well as relevant real-life examples and policy developments. There is also room for discussion and questions with clear answers.
Celgene
Esther Berden, Associate Director Government Relations & Policy Europe - Belgium - May 2019 (face-to-face course)A practical approach in the elements of Market Access.
Santhera
Jur Van der Wild, Market Access Manager EU - The Netherlands - May 2019 (face-to-face course)Very good overview of connected topics/processes. Lieven’s teaching style is excellent. Thanks!
Bayer
Mimi De Ruyck, Head Market Access & Stakeholders Management - Belux - November 2018 (face-to-face course)Great lecturer with big experience in this field.
Sanofi
Mirela Horvat Kiš, Public Affairs and Market Access Country Head - Croatia - November 2018 (face-to-face course)An excellent and highly informative course delivered with charisma and humour - thank you!
BresMed Health Solutions
James Horscroft, Senior Insights Analyst - United Kingdom - November 2018 (face-to-face course)Learning the key aspects of HTA in one day is doable! Inspiring course to understand WHY/HOW/WHAT a good HTA stands for. Great value!
Purman Consulting
Gabor Purman, Behavioral Economist - The Netherlands - April 2018 (face-to-face course)Highly professional course addressing key topics of HTA.
Bayer
John Claessens, Head RA & QP - The Netherlands - April 2018 (face-to-face course)Emerging reimbursement opportunities in the context of medical nutrition makes HTA a key topic.
Nutricia Advanced Medical Nutrition
Tomasz Rudka, Medical Affairs Manager - Belgium - April 2018 (face-to-face course)Another great course by Prof. Annemans!
Amgen
Eduard Sidelnikov, Health Economics Senior Manager - Switzerland - November 2017 (face-to-face course)This course is structured, interactive and helpful! The 3 most valuable aspects are: the core perspectives of HTA, the impact on regulatory decisions and the future developments.
Merck
Georgios Amexis, Director Global Regulatory Lead, RAC - Germany - May 2017 (face-to-face course)Great overview of HTA with a very enthusiastic speaker.
AstraZeneca
Pieter Van Bochaute, Medical Science Liaison - Belgium - December 2016 (face-to-face course)Quite a broad subject that was well-explained. By attending this course, you will understand the most recent trends and get interesting examples.
UCB
Solène Thieffry, Senior Health Outcomes Manager - Belgium - December 2016 (face-to-face course)A great overview of the HTA landscape and challenges/opportunities presented in a perfect mix of theory and practical examples – and everything in just one day!
Johnson & Johnson
Andreas Preising, Director Government Affairs & Policy EMEA - Belgium - June 2016 (face-to-face course)This 1-day HTA course with Prof Lieven Annemans was extremely useful as I learnt about joint initiatives, how to get into dialogue in an early phase, harmonization, the criteria, do’s & don’ts etc. Highly recommendable!
Siemens Healthcare
Dr. Bernhard Fahn, Head of Health Economics & Outcome Research, Medical Office - Germany - June 2016 (face-to-face course)Very well-organised HTA course with great content from one of the brightest industry experts!
Wellmera
Dr. Rosemary Jose, Senior Consultant - Switzerland - June 2016 (face-to-face course)All the information in this C.E.L.forpharma 1-day HTA course was relevant for my role. I particularly liked the example-based learning approach and would have loved a 2nd day to dive deeper.
Janssen
Irina Vasiliu, Market Access Specialist - Romania - June 2016 (face-to-face course)Great training and content on HTAs, very well adapted to the audience with concrete examples and relevant tips and tricks.
Teva
Nathalie Plasman, Therapeutic Area Manager - Belgium - June 2016 (face-to-face course)The course was extremely well organised and had the appropriate expert. Thank you!
UCB
Mata Charokopou, Senior Manager Health Economics, Global Payer Evidence - Belgium - December 2015 (face-to-face course)An extremely valuable course for beginners to HTA!
European Generic Medicines Association
Deniz Kocas, Economics Advisor - Belgium - October 2015 (face-to-face course)I am extremely happy that I could attend this course - Prof. Annemans made a complicated subject very accessible.
Intermed
Gülce Belgin, Owner/General Manager - Turkey - October 2015 (face-to-face course)I value this course a lot as it gave me that missing piece of understanding I was looking for. Prof. Annemans has prepared a truly comprehensive overview of HTA, at the end of which one clearly understands the basic principles behind the assessment, how the process currently works and how it ideally should work. I recommend this course to everyone looking for that missing piece!
Bristol-Myers Squibb
Leila Zajac, Regulatory Manager Distributor Markets Europe - Austria - October 2015 (face-to-face course)An excellent overview! Well worth the trip and a day away from the office. I will return to the office better able to discuss and probe HTA-related issues and opportunities with colleagues and health policy stakeholders.
Novartis
John-Kenneth Billingsley, Senior Director European Government Affairs - Switzerland - June 2015 (face-to-face course)This was a very interesting course! As I just started working as a medical project manager in the pharmaceutical industry, I learned a lot!
Gilead
Kim Vanstraelen, Medical Project Manager - Belgium - June 2015 (face-to-face course)I find this training very useful and fitting to the current needs. Nowadays when developing a program, not only a close interaction with the regulatory agencies is critical but a timely collaboration with HTA stakeholders is required as well.
Bayer
Monica Bratti, Global Regulatory Strategist - Germany - June 2015 (face-to-face course)This course gave me an opportunity to take a look into HTA from a broader perspective. I would recommend this course to health authorities. Thank you very much!
Institute of Hygiene
Raimonda Janoniene, Research and Technology Assessment Manager - Lithuania - June 2015 (face-to-face course)The best, clearest and most easy to understand explanation of HTA I've ever heard, really! The slides are really good (even pictures are chosen perfectly)!
Novartis
Adelina Afzalova, Health Economics and Outcomes Research Manager - Russia - March 2015 (face-to-face course)This very helpful Health Technology Assessment course will support me a lot in my daily work!
Baxter
Claudia Lentner-Böhm, Head of Health Economics Hospital Care DACH - Germany - March 2015 (face-to-face course)Lieven Annemans is an excellent speaker with the ability to provide an excellent 'helicopter view' of a very complex landscape.
UCB Pharma
Marcel Brink, Director Regulatory Affairs - Belgium - March 2015 (face-to-face course)In one day Lieven Annemans demystifies HTA.
AstraZeneca
Toke Skovlund, Director Government Affairs & Global Brands - United Kingdom - March 2015 (face-to-face course)Lieven is an excellent speaker who kept the group engaged throughout the day. I particularly appreciated his ability to relate to pharma executives' real-life experiences.
Shire
Oswald Bentinck, Global Market Access Director - Switzerland - November 2014 (face-to-face course)Very efficient learning and a healthy mix of depth and breadth. Congratulations for a successful first HTA training!
Novartis
Stefan Weber, Director, Payment Policy - Switzerland - November 2014 (face-to-face course)The Dos and Don'ts in Health Technology Assessments is an excellent program. Prof. Annemans delivers a very practical single day overview encompassing where companies typically fall short and which areas are essential to optimise chances of a successful outcome. I highly recommend this interactive course both to those working in the area and those simply looking to enhance their knowledge of HTA.
Biogen Idec International
Tim McCormick, VP Business Operations - Switzerland - November 2014 (face-to-face course)Very clear and well presented! As evidenced by his responses to questions, Lieven has a lot of expertise in this matter. He offered great examples in his HTA course.